Announcement PDF Transforming Nerve Repair Through Science ReNerve Company presentation | Shareholder half year update webinar March 2026 ASX:RNV ReNerve Company presentation | March 2026 Important Notice & Disclaimer 2 Nature of Document: This presentation has been prepared and issued by ReNerve Ltd (Company) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While management has taken every effort to ensure the accuracy of the material in this presentation, the Company have not verified the accuracy or completeness of the material contained in this presentation. Not an offer: this presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be unlawful under the securities or other laws of that or any other jurisdiction. Not financial product advice: You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision. Forward looking statements: This presentation contains forward-looking information about the Company and its operations. In certain cases, forward-looking information may be identified by such terms as "anticipates", "believes", “should”, "could", "estimates", “target”, “likely”, “plan”, "expects", "may", “intend”, "shall", "will", or "would". These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to risk factors associated with the Company’s business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. Disclaimer: No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any effort or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice. An offer of Shares in ReNerve Ltd (ABN 23 614 848 216) is being made in or accompanied by a prospectus dated at a date to be confirmed. Anyone who wants to acquire Shares pursuant to the offer will need to complete the application form that accompanies the prospectus. A person should consider and rely only on the prospectus in deciding whether to invest. A copy of the prospectus is available by contacting the Company or by downloading from the Company’s website (www.renerve.com.au). Speculative nature of investment: Any potential investor should be aware that subscribing for Shares involves various risks. The Shares to be issued pursuant to the Prospectus lodged with ASIC by ReNerve Ltd carry no guarantee with respect to the payment of dividends, returns of capital or the market value of those Shares. An investment in Shares of the Company should therefore be considered very speculative. ReNerve Ltd ABN 23 614 848 216 ReNerve Company presentation | March 2026 ReNerve is developing a comprehensive portfolio of products for the nerve repair and regeneration markets and related surgical procedures, with clearly defined commercial position and demand. Executive Summary 3 Executive Summary 3 product ranges in the US market with more coming in 2026 ReNerve has established logistics, warehouse and invoicing infrastructure with a strong focus on building a sales distribution network for all products in the US and beyond. Successful ongoing expansion within the first year of ASX listing into Ex-US markets in Asia, India, The Middle East, and The Americas. Improved patient outcomes for post-surgical measures of pain and surgery satisfaction, as well as proven ease of use for surgeons. Development of Novel Nerve Repair & Regeneration Products Expanding Product Portfolio Strong Sales & Distribution Presence Global Expansion & Commercialisation Clinical & Professional Validation ReNerve Company presentation | March 2026 Dr Alex Adamides MD FRACS Chief Medical Officer (CMO) Dr Paul Savage Independent Non- executive Director Maja McGuire Independent Chair Dr David Rhodes CSO & Director Dr Julian Chick CEO & Managing Director Board and Management Leadership Team 4 ReNerve appointed a new, market experienced Chair and Non-Executive Director with extensive public market and corporate governance experience with an experience in medical devices. New board members join ReNerve Company presentation | March 2026 Revenue for the half of $163,719, up 60.2% from the corresponding period Executive Summary 5 Half year highlights Revenue up 60.2% Cash of $4.18M With an additional $0.6m to received in Q1 CY26 from the Company’s $3.2m capital raising (announced 20/11/26) and the R&D tax rebate $0 $20,000 $40,000 $60,000 $80,000 $100,000 $120,000 ReNerve quarterly sales '23 to ‘25 (AUD$) ReNerve Company presentation | March 2026 Executive Summary 6 Half year highlights NervAlign® approved for use in US Department of Defense (DoD) & Veterans Affairs (VA) healthcare systems • NervAlign® Nerve Cuff approved for use in DoD and VA hospitals • Initial order and reorder received from the DoD and VA network • Further validation of the quality of NervAlign® in peripheral nerve repair • Allows the NervAlign® Nerve Cuff to be used across the DoD's 51 military hospitals and 424 clinics, as well as VA's 170 medical centres and over 1,193 outpatient facilities ReNerve Company presentation | March 2026 Executive Summary 7 Half year highlights Regulatory & development milestones across the NervAlign® range • Additional regulatory approvals for NervAlign® Nerve Cuff in Hong Kong & Malaysia • Further progress in India for the NervAlign® Nerve Cuff approval • Key development milestones for the NervAlign® Nerve Conduit to achieve market entry in 2026 • Prototype production for the NervAlign® Nerve Guide Matrix moving to next stage in 1H 2026 ReNerve Company presentation | March 2026 Executive Summary 8 Half year highlights EmpliQ tissue product range launched • First sales of the EmpliQ human tissue products announced • First sales of amniotic tissue range announced • Highlights the importance of ReNerve’s strategic partnership with Berkeley Biologics LLC • The dermal and amniotic tissue market is estimated to reach more than $1.5 billion in 2026 and more than $3 billion by 2032¹ 1 MarketWide Research – Dermal and Amniotic tissue market report 2025-2032, Published 2025 ReNerve Company presentation | March 2026 Executive Summary 9 Catalysts CY26 Continued focus on sales expansion with first direct sales reps now full-time Approval for the NervAlign® Nerve Cuff in India, a major market opportunity European approval submission, utilising the data from the 'Align' study Approval across additional south-east Asian jurisdictions Market launch of the 1st NervAlign® Nerve Conduit Continued development of the NervAlign® Nerve Guide Matrix Growth of the EmpliQ brand ReNerve Company presentation | March 2026 Nerve Cuff Nerve Tube Nerve Protector Nerve Guide Matrix Nerve Cap Dermal Tissue AmnioLite AmnioDuo Placental R&D Product Development Commercial Development On Market Product Company Portfolio 10 ReNerve Company presentation | March 2026 Target Market USD$2.0Bn USD$6.0Bn Global Nerve Repair Biomaterial Market USD$1.0Bn 2025 USD$6.19Bn USD$1.90Bn USD$1.10Bn The Global Nerve Repair Biomaterials Market is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD$6.19Bn. 2031 Our Target Markets Dermal and Amniotic Tissue Surgical Applications (Trauma, plastic surgery) Dermal and Amniotic Tissue Orthopedics (Tendon and Ligament MarketWide Research – Dermal and Amniotic tissue market report 2025- 2032, Published 2025. 11 Value drivers for the next 12 months Driving sales and new products into market ● Complements the nerve products sales ● Anticipating faster sales growth through multiple products ● Conduit product coming to market to build out the product portfolio Empliq products ranges now in the US market ● Direct sales team in the US to support distributor network ● Increasing hospital approvals ● Rising sales with multiple product ranges in market Working with distributors for additional approvals ● Strong, positive data in 2025 ● Ability to definitive clinical study ● The “Align” study underway and actively recruiting ● Initial data due in 2026 Ongoing Clinical Study ● Establishing partners Ex-USA ● Pending approval in several countries in 2026 ● Leveraging existing clinical data and cases to expand globally ● Follow the same path for new products Continue to expand into Ex- US markets 2026 about major commercial progress 12 ReNerve Company presentation | March 2026 Investment Highlights In Market Products Immediate Market Need Growing Market Diverse Product Portfolio Growing Distribution Board & Management Nerve Cuff transitioned from R&D to commercial sales with 3 product lines in market and nerve coduits coming. Products promote nerve injury recovery and wound repair leading to faster patient recovery and better outcomes. Nerve repair biomaterials and related markets are forecast to grow by >17% pa, estimated to be worth >US$6.19Bn by 2031. USD$1Bn+ market for human tissue product ranges Building a complete product range in market with 3 in market and more coming in 2026. Additional products currently under development. Continuing to build sales representation with a targeted-direct sales approach. Expanding globally. Highly accomplished executive team with a proven track record in the development & commercialisation of medical opportunities. 13 ReNerve Company presentation | February 2026 ReNerve Company presentation | March 2026 Contact Us ReNerve Limited info@renerve.com.au Level 10/99 Queen St, Melbourne, Victoria 3000 Australia +61 (03) 9482 3940